{
}
Teva/Sanofi's Phase IIb data for their anti-TL1A agent in ulcerative colitis and Crohn’s disease has been described as potentially best in class, raising competitive stakes against Merck and Roche. Meanwhile, PureTech's deupirfenidone has outperformed Roche's Esbriet in a Phase IIb trial for idiopathic pulmonary fibrosis, positioning the company to finalize its Phase III program and explore financing options.
Congress is nearing a deal to regulate pharmacy benefit managers (PBMs), aiming to enhance transparency and limit their payment structures in Medicare and Medicaid as part of a government funding package. Meanwhile, Sanofi has sued the Biden administration over restrictions on changing payment terms for hospitals in the 340B Drug Discount Program, claiming the HRSA is siding with hospitals against manufacturers.
Stocks slipped as the Dow fell for the ninth consecutive day, its longest slump since 1978, ahead of the Federal Reserve's rate decision. Teva and Sanofi shares soared after positive drug trial results, while Amentum and EVgo faced declines due to concerns over future growth and investor sell-offs, respectively. Pfizer's shares rose after affirming its 2024 projections and providing a 2025 outlook in line with expectations.
Teva and Sanofi's experimental drug, duvakitug, demonstrated significant efficacy in a Phase 2 trial for inflammatory bowel disease, with around 50% of ulcerative colitis patients and 48% of Crohn’s disease patients showing symptom resolution compared to placebo. The companies plan to advance to late-stage development, highlighting duvakitug's potential as a leading treatment in a competitive market. Following the promising results, Teva's shares surged nearly 20%, while Sanofi's rose by almost 5%.
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
The Global Bromhexine Tablet market is projected to grow from USD 875.5 million in 2023 to USD 1,131.7 million by 2032, with a CAGR of 3.7% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory disorders and increasing demand for expectorants. Key players include Sanofi, Teva, and Boehringer Ingelheim, with market segmentation covering applications, types, and distribution channels across various regions.
Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
The Mobile Medicine market is rapidly evolving, driven by innovative technologies and a competitive landscape featuring key players like Philips Healthcare, Apple, and Samsung. The market report highlights regional growth assessments, product segmentation, and forecasts from 2024 to 2031, focusing on applications in cardiovascular, diabetes, and respiratory diseases. Comprehensive analyses of market trends, driving factors, and the impact of COVID-19 provide insights into investment opportunities across North America, Europe, Asia-Pacific, and Latin America.
India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
The incoming Trump administration and a Republican-controlled Congress are expected to significantly impact healthcare policy, particularly regarding the Affordable Care Act, Medicaid, and Medicare drug price negotiations. Analysts predict a net negative effect on healthcare companies' credit ratings due to potential increases in uninsured populations and regulatory changes, while decreased scrutiny on mergers and acquisitions may benefit the pharmaceutical sector. Additionally, rising tariffs on medical supplies could further strain the industry amid ongoing inflationary pressures.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Teva and PureTech report promising Phase IIb trial results in key therapies
23:56 17.12.2024
Congress moves to regulate pharmacy benefit managers amid Sanofi lawsuit
15:32 17.12.2024
stocks decline as dow extends losing streak ahead of fed decision
United States Dollar
Pfizer Inc.
Jacobs Solutions Inc.
EVgo, Inc.
Amentum Holdings, Inc.
Sanofi
USA
Jerome Powell
Aaron McDade
Taylor Tompkins
Houman Ashrafian
Travis Johnson
Show more
13:56 17.12.2024
duvakitug shows promise as best in class for inflammatory bowel disease
01:00 17.12.2024
global bisoprolol fumarate market poised for significant growth through 2032
United States Dollar
Merck & Co., Inc.
Amgen Inc.
Alkem Laboratories Limited
Mylan Pharmaceuticals Inc.
Aurobindo Pharma Limited
Teva Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Limited
Glenmark Pharmaceuticals Limited
CIPLA LTD
Sandoz Group AG
Pfizer Inc.
Bayer AG
Hikma Pharmaceuticals PLC
AstraZeneca PLC
Novartis AG
Torrent Pharmaceuticals Limited
Sanofi
IND
ROU
BEL
HUN
DNK
POL
IDN
SGP
ARE
BRA
ZAF
FRA
THA
MEX
CZE
GBR
CHL
AUT
SAU
SWE
NOR
NLD
USA
ARG
MYS
SVK
CAN
NZL
LKA
JPN
DEU
RUS
KOR
CHN
VNM
Nidhi Bhavsar
Show more
13:09 16.12.2024
global bromhexine tablet market projected to reach 1131 million by 2032
GSK plc
Aspen Pharmacare Holdings Ltd
Boehringer Ingelheim KG
Novartis AG
Sanofi
MYS
IND
PHL
IDN
HKG
SGP
TWN
JPN
THA
AUS
KOR
CHN
VNM
Nidhi Bhavsar
Show more
08:02 14.12.2024
gilead appoints dietmar berger as new chief medical officer from sanofi
United States Dollar
Hoffmann-La Roche AG
Gilead Sciences, Inc.
Bayer AG
Immunomedics Inc.
Genentech
Amgen Inc.
Sanofi
USA
FRA
John S. Reed
Houman Ashrafian
Daniel O'Day
Merdad Parsey
Dietmar Berger
Show more
11:20 13.12.2024
Global Mobile Medicine Market Trends and Opportunities for Growth 2024 to 2031
United States Dollar
Euro
BOSTON SCIENTIFIC
Omron Healthcare
NIKE, Inc.
Huawei Technologies CO. Ltd.
Athenahealth Inc.
Philips Healthcare
XIAOMI-W
Sanofi
Fitbit
Bayer HealthCare AG
Apple Inc.
Masimo Corp
Samsung Biologics Co.,Ltd.
Qualcomm Inc
Medtronic plc
AT&T Inc.
Gauri Dabi
Show more
10:57 05.12.2024
Global Generic Pharmaceuticals Market Sees Growth in Simple Generics and Biosimilars
United States Dollar
Euro
Fresenius Kabi AG
Sanofi
Aspen Pharmacare Holdings Ltd
Sun Pharmaceuticals, Ltd.
Aurobindo Pharma Limited
Glenmark Pharmaceuticals Limited
Pfizer Inc.
Lupin Limited
Dr. Reddy's Laboratories Limited
Zydus Lifesciences Limited
Teva Pharmaceuticals, Inc.
Viatris Inc.
Novartis AG
Hikma
Cipla Limited
IND
USA
Show more
16:30 04.12.2024
Republican Control Promises Major Shifts in Healthcare and Pharma Policies
United States Dollar
AstraZeneca PLC
Sanofi
Merck & Co., Inc.
Pfizer Inc.
GSK plc
IND
USA
CHN
Mike Johnson
Robert F. Kennedy Jr.
Donald Trump
Lina Khan
Show more
23:30 03.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Cryptocurrency Trends
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Central Banks and Digital Currencies
CEO Changes
Workplace Trends
Blockchain Infrastructure Development
Banking Regulations
Central Bank Actions
Retail and Consumer Goods
Private Equity Deals
Global Financial Events
Government Economic Policies
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Vodafone Idea Limited
JM Financial Limited
Fuse Science, Inc.
Arla Foods A.M.B.A.
Currencies:
People: